Drug Pricing Policy: What’s on the Horizon?
Summary
Avalere experts examine the current drug pricing policy landscape and what potential changes stakeholders should prepare for.
Please note: This is an archived post. Some of the information and data discussed in this article may be out of date. It is preserved here for historical reference but should not be used as the basis for business decisions. Please see our main Insights section for more recent posts.
The recent proposal by the administration to require manufacturers to disclose list prices in direct-to-consumer (DTC) advertising is the latest in a wave of recent policy activity focused on prescription drugs at the state and federal levels. This includes noteworthy activity such as allowing indication-based formularies in Part D and step therapy in Medicare Advantage, soliciting feedback on new models to manage Part B drugs, and state efforts to manage Medicaid drug costs. So what’s next?
Avalere experts recap recent policy action and preview future policy activity focused on prescription medications. This webinar provides insights into potential changes, market impacts, and considerations for healthcare stakeholders.
Topics covered:
- Potential action on management of physician-administered drugs
- Manufacturer rebates
- State management of drugs in Medicaid
- Part D reforms
Panelists
Related Content
Services
From beginning to end, our team synergy
produces measurable results. Let's work together.
produces measurable results. Let's work together.
